symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
MIRA,3.16,0,99857,46707644,0,2.76-6.95,0.13,"MIRA Pharmaceuticals, Inc.",USD,0001904286,,,NASDAQ Capital Market,NASDAQ,Drug Manufacturersâ€”General,https://mirapharmaceuticals.com,"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.",Mr. Erez  Aminov,Healthcare,US,2,737-289-0835,855 North Wolfe Street,Baltimore,MD,21205,,0,https://financialmodelingprep.com/image-stock/MIRA.png,2023-08-14,True,False,True,False,False
